Lyntonix is a spin-off startup company established in 2025 by the original National Taiwan University (NTU) irritable bowel syndrome (IBS) new drug team; the key members are Professor Ling-Wei Hsin (School of Pharmacy), Professor Linda Yu (Institute of Physiology), and Superintendent Ming-Shian Wu (NTU Hospital).

Our mission is to provide novel, non-addictive solution for various chronic pain for which there is currently no satisfactory clinical treatment, to relieve the physical and mental suffering and stress caused by long-term pain, so that patients can regain a dignified and high-quality daily life.

Current goal is focused on developing novel drugs and therapeutic strategies for treating abdominal pain in irritable bowel syndrome (IBS). Lyntonix has identified the mechanism underlined the IBS-related abdominal pain and novel drug target. This breakthrough led to the successful development of LTX-568, a first-in-class drug candidate possessing superior analgesic efficacy with excellent safety profile. LTX-568 has the potential to become a first-line treatment for visceral hypersensitivity and can be used to treat abdominal pain across various IBS subtypes, which demonstrating huge market potential. The non-GLP preclinical studies, including pharmacology, pharmacokinetics, and toxicology assessments, have been completed. Lyntonix plans to complete angel-round fundraising in 2025, start the GLP studies, submit IND applications in the United States and Taiwan in 2026, and conduct the Phase I human clinical trial in 2027.

LYNTONIX was founded on March 25, 2025.
Correspondence address：17, Xuzhou Road, Room 936, Taipei, 100 Taiwan

Services: New drug discovery